Jazz Pharmaceuticals: specialty pharma cash flow needs pipeline and portfolio proof
Jazz Pharmaceuticals reported 2025 revenue of $4.27 billion and Q1 2026 revenue of $1.07 billion. The thesis turns on whether specialty medicines, pipeline investment and portfolio execution can convert strong cash generation into durable earnings after a loss
Open